吉西他滨辅助治疗蒽环类耐药的晚期乳腺癌的疗效观察  

Efficacy of Gemcitabine Adjuvant Therapy for Anthracycline Resistant Advanced Breast Cancer

作　　者：罗丹凤[1] 洪朝欣 

机构地区：[1]解放军第180医院,362000

出　　处：《实用癌症杂志》2017年第8期1358-1360,1363,共4页The Practical Journal of Cancer

摘　　要：目的探讨吉西他滨辅助治疗蒽环类耐药的晚期乳腺癌的疗效。方法采用回顾性研究方法。选择蒽环类耐药的晚期乳腺癌患者120例作为研究对象,根据治疗方法的不同分为观察组与对照组,各60例。观察组给予吉西他滨辅助治疗,对照组给予长春瑞滨辅助治疗,21 d为1个化疗周期,2组都治疗3个周期。结果观察组的有效率为70.0%,对照组的有效率为50.0%,观察组的有效率明显高于对照组(P<0.05)。观察组与对照组白细胞下降、恶心呕吐、黏膜反应等不良反应发生率对比,差异无统计学意义(P>0.05),且对症处理后均明显好转。随访至今,观察组的无进展生存时间和总生存期为(16.39±2.19)个月和(19.44±1.87)个月,都明显长于对照组的(13.22±1.89)个月和(16.98±2.22)个月(P<0.05)。结论吉西他滨辅助治疗蒽环类耐药的晚期乳腺癌具有较好的安全性,能提高治疗效果,从而延长患者的生存时间,有较高的应用价值。Objective To investigate the efficacy of gemcitabine adjuvant therapy for anthracycline resistant advanced breast cancer. Methods A retrospective study was conducted, 120 advanced breast cancer patients with anthracycline drug re- sistance were selected as the research object, all the patients were divided into the observation group and the control group, with 60 patients in each group according to the different treatment methods, the observation group was given adjuvant gemcitabine treat- ment, the control group was given vinorelhine adjuvant therapy,21 d for 1 cycle, the 2 groups were observed for 3 cycles of treat- ment. Results The effective rates of the observation group was 70.0% , the effective rate of the control group was 50.0% , and the effective rate of the observation group was significantly higher than that of the control group（ P 〈 0.05 ）. There were no signifi- cant difference between the 2 groups in the incidence of leukopenia, nausea and vomiting, mucosal reaction and other adverse re- actions （ P 〉 0.05 ） , and all the adverse reactions after symptomatic treatment significantly improved. Up to now, the progression free survival and overall survival in the observation group were（ 16.39 ±2.19） months and（ 19.44 ± 1.87） months,which were significantly longer than those of the control group of（ 13.22 ± 1.89） months and （ 16.98 ±2.22 ） months （ P 〈 0.05 ）. Conclu- sion Gemcitabine adjuvant therapy for anthracycline resistant advanced breast cancer has good safety,it can improve the thera- peutic effect, prolong the survival time of patients, and it has high application value.

关 键 词：吉西他滨 蒽环类药物 耐药性 晚期乳腺癌 生存时间 

分 类 号：R737.9[医药卫生—肿瘤]